Melanoma Institute Australia, Sydney, NSW, Australia.
Pigment Cell Melanoma Res. 2013 Sep;26(5):611-5. doi: 10.1111/pcmr.12132. Epub 2013 Jul 19.
Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon preclinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors and provides a strategic approach to understand this issue further.
皮肤鳞状细胞癌（cSCC）是 BRAF 抑制剂治疗黑色素瘤时令人担忧的一种毒性。虽然两种药物——vemurafenib 和 dabrafenib——都显示出改善生存的效果，但它们的 cSCC 报告率却有很大的不同。本文参考了临床前和临床试验数据，讨论了两种 BRAF 抑制剂报告的不同 cSCC 发生率背后的潜在因素，并提供了一种进一步理解这个问题的策略方法。
